Report #2835229

Received Apr 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 54 yrs
State: OR
Recovered: Unknown
Vaccinated: Apr 3, 2025
Onset: Apr 3, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	TY7MZ	—

Symptoms (1)

Incorrect route of product administration

Symptom narrative

Wrong Route of Administration; This non-serious case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a 54-year-old female patient who received Herpes zoster (Shingrix) (batch number TY7MZ) for prophylaxis. On 03-APR-2025, the patient received the 1st dose of Shingrix. On 03-APR-2025, an unknown time after receiving Shingrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Wrong Route of Administration). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 04-APR-2025 The registered nurse reported that the patient given Shingrix with subcutaneous route by accident and wanted to know if there was any protocol for this, which led to intramuscular formulation administered by other route.